Lumateperone, sold under the brand name Caplyta, is an atypical antipsychotic medication of the butyrophenone class. It is approved for the treatment of schizophrenia as well as bipolar depression, as either monotherapy or adjunctive therapy (with lithium or valproate).[2] It is developed by Intra-Cellular Therapies, licensed from Bristol-Myers Squibb.[3] Lumateperone was approved for medical use in the United States in December 2019 with an initial indication for schizophrenia,[4][5] and became available in February 2020.[2] It has since demonstrated efficacy in bipolar depression and received FDA approval in December 2021 for depressive episodes associated with both bipolar I and II disorders.
^"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
^ abcdefgCite error: The named reference Caplyta FDA label was invoked but never defined (see the help page).
^Celanire S, Poli S, eds. (13 October 2014). Small Molecule Therapeutics for Schizophrenia. Springer. pp. 31–. ISBN 978-3-319-11502-3.
^Cite error: The named reference FDA snapshot was invoked but never defined (see the help page).
^Cite error: The named reference FDA approval was invoked but never defined (see the help page).
Lumateperone, sold under the brand name Caplyta, is an atypical antipsychotic medication of the butyrophenone class. It is approved for the treatment of...
commonly used antipsychotic (200 times more potent than chlorpromazine) Lumateperone, an atypical antipsychotic used for schizophrenia and bipolar depression...
(Solian) – approved in low doses as a monotherapy for persistent depression Lumateperone (Caplyta) – approved as a monotherapy for bipolar depression Lurasidone...
of first-generation (typical) antipsychotics. Lumateperone (Caplyta) – In December 2019, lumateperone, a presynaptic D2 receptor partial agonist and...
the FDA in the United States. Cariprazine, Quetiapine, lurasidone, and lumateperone have been approved, as monotherapies, for bipolar depression, but as...
Global Information
